尿液糖胺聚糖评分用于中高危非转移性透明细胞肾细胞癌复发监测
这项观察性前瞻性多中心诊断试验队列研究纳入134例术后Leibovich评分≥5分的M0 ccRCC患者,每3个月检测尿液GAGome评分并以影像学复发为参考标准。GAGome评分对影像学复发的敏感性为90%、特异性为51%,阴性预测值97%,中位领先时间4.2个月。
要点
- GAGome评分敏感性90%、阴性预测值97%,阴性结果对排除复发有较高价值。
- 评分阳性者中位领先影像学复发4.2个月,可能提前提示复发。
- 随访时间短,外部验证尚待完成,暂不宜单独替代影像随访。
核心结论
- 尿液GAGome评分对M0 ccRCC术后复发具有很高敏感性,阴性预测值达97%,有望用于个体化随访。
研究设计与样本
- 观察性前瞻性多中心诊断试验队列研究;筛查393例,134例Leibovich评分≥5分的术后M0 ccRCC患者纳入分析。
主要发现
- 末次随访时16%患者复发;GAGome评分敏感性90%(95%CI 62-100%),特异性51%(95%CI 30-71%)。
- 阳性预测值26%(95%CI 4-46%),阴性预测值97%(95%CI 87-100%)。
- 首次阳性评分至影像学复发的中位领先时间为4.2个月(IQR 1.6-6.4)。
- GAGome评分每增加10分,复发HR为1.62(95%高密度区间1.11-2.30)。
关键数值与推荐
- 纳入标准为术后M0 ccRCC且Leibovich评分≥5分。
- 每3个月检测尿液GAGomes计算GAGome评分,随访影像至18个月作为参考标准。
- 无复发者中位随访16个月(IQR 12-18)。
临床怎么用
- 可将GAGome评分作为影像随访之间的补充监测工具,阴性结果有助于降低复发疑虑。
- 评分阳性提示需更密切影像随访,但阳性预测值仅26%,需结合影像确认。
局限性
- 主要局限性为随访时间短。
- 外部验证尚在研究设计之中,尚未完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Nonmetastatic (M0) clear cell renal cell carcinoma (ccRCC) recurs in ∼20% of patients within 5 yr after surgery. With no biomarkers available, recurrence detection relies on radiological imaging. Urine glycosaminoglycan profiles (GAGomes) were previously associated with M0 ccRCC recurrence. We conducted an observational prospective multicentre diagnostic test cohort study to evaluate GAGomes for postsurgery recurrence detection in M0 ccRCC. METHODS: Postsurgical M0 ccRCC patients with a Leibovich score of ≥5 points were included. Follow-up imaging up to 18 mo assessed radiological recurrence (reference standard). Urine GAGomes were measured every 3 mo to compute a GAGome score (index test). Sensitivity and specificity to radiological recurrence were calculated. The lead time between the first positive GAGome score and radiological recurrence was estimated. Bayesian joint modelling estimated recurrence-free survival hazard ratio (HR). KEY FINDINGS AND LIMITATIONS: Of the 393 patients screened (January 2020 to November 2021), 134 met the inclusion criteria. The median follow-up was 16 mo (interquartile range [IQR]: 12-18) for those without recurrence. At the last follow-up visit, 16% had recurred. The GAGome score had 90% sensitivity (95% confidence interval [CI]: 62-100%) and 51% specificity (95% CI: 30-71%) to radiological recurrence. The positive and negative predictive values were 26% (95%CI: 4-46%) and 97% (95% CI: 87-100%), respectively. The median lead time was 4.2 mo (IQR: 1.6-6.4). A 10-point GAGome score increase was associated with an HR of 1.62 (95% high density interval: 1.11-2.30) for recurrence. The main limitation was short follow-up time. CONCLUSIONS AND CLINICAL IMPLICATIONS: GAGome score had very high sensitivity to ccRCC recurrence, resulting in a negative predictive value of 97%. External validation foreseen in the study design aims to confirm its utility to personalise follow-up for M0 ccRCC patients.
引用
- Dabestani S, Azawi NH, Campi R, et al. Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study. Eur Urol Oncol. 2025. PMID: 40866172. doi:10.1016/j.euo.2025.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。